staurosporine has been researched along with Experimental Neoplasms in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (43.75) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| An, Y; Jeon, R; Kang, JS; Kim, WY; Lee, E; Lee, MY; Yu, Y; Yun, J | 1 |
| Cao, D; Chen, YL; Damaneh, MS; Hu, J; Li, Y; Meng, T; Miao, Z; Shen, J; Song, S; Wang, X; Wang, Y; Xiong, B; Xu, L | 1 |
| Abouzid, KAM; Esmat, A; Hossam, M; Ismail, NSM; Lasheen, DS; Mansour, AM; Singab, ANB | 1 |
| Cheng, M; Gu, J; Guo, J; Hao, C; He, Z; Liu, Y; Pang, Y; Wang, T; Wu, T; Yin, W; Zhang, K; Zhao, D; Zheng, J; Zhu, M | 1 |
| Bharati, IS; Chao, Y; Fogal, V; Jiang, P; Kesari, S; Makale, M; Mukthavaram, R; Nomura, N; Pastorino, S; Pingle, SC; Saklecha, R; Simberg, D; Wrasidlo, W | 1 |
| Angeles, TS; Mallamo, JP; Tripathy, R; Yang, SX | 1 |
| Aslanian, AS; Lees, JA; Reinhardt, HC; Yaffe, MB | 1 |
| Hargrove, ME; Shiver, J; Ting, CC; Wu, J | 1 |
| Akinaga, S; Gomi, K; Nomura, K; Okabe, M | 1 |
| Beltran, P; Fan, D; Fidler, IJ; Killion, JJ; O'Brian, CA; Wilson, MR; Yoon, SS | 1 |
| Fujita, F; Fujita, M; Ikegami, Y; Isowa, K; Murata, N; Nakao, K; Sakamoto, Y; Yano, S | 1 |
| Saijo, N | 1 |
| Akinaga, S; Akiyama, T; Fuse, E; Kobayashi, H; Kobayashi, S; Kurata, N; Kuwabara, T; Tanii, H; Yamaguchi, K | 1 |
| Bodis, S; Fabbro, D; Glanzmann, C; Hegyi, I; Oehler, C; Pruschy, M; Resch, H; Rocha, S; Zaugg, K | 1 |
| Abe, S; Akinaga, S; Akiyama, T; Furukawa, T; Kitajima, M; Kubota, T; Kumai, K; Otani, Y; Watanabe, M | 1 |
| Akinaga, S; Gomi, K; Morimoto, M; Okabe, M; Tamaoki, T | 1 |
1 review(s) available for staurosporine and Experimental Neoplasms
| Article | Year |
|---|---|
New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.
Topics: Alkaloids; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Glucosides; Humans; Irinotecan; Japan; Lung Neoplasms; Mitomycin; Mitomycins; Neoplasms, Experimental; Paclitaxel; Purine Nucleosides; Staurosporine; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
15 other study(ies) available for staurosporine and Experimental Neoplasms
| Article | Year |
|---|---|
Design and synthesis of novel benzoxazole analogs as Aurora B kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Aurora Kinase B; Benzoxazoles; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Humans; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Structure-Activity Relationship | 2016 |
Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Nuclear Proteins; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Quinoxalines; Structure-Activity Relationship; Transcription Factors; Xenograft Model Antitumor Assays | 2017 |
Discovery of anilino-furo[2,3-d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Mice; Molecular Structure; Neoplasms, Experimental; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Tumor Cells, Cultured | 2018 |
Synthesis, bioconversion, pharmacokinetic and pharmacodynamic evaluation of N-isopropyl-oxy-carbonyloxymethyl prodrugs of CZh-226, a potent and selective PAK4 inhibitor.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; Liver; Male; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; p21-Activated Kinases; Piperazines; Prodrugs; Protein Kinase Inhibitors; Rats; Rats, Wistar; Structure-Activity Relationship | 2020 |
High-efficiency liposomal encapsulation of a tyrosine kinase inhibitor leads to improved in vivo toxicity and tumor response profile.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Diffusion; Female; Humans; Liposomes; Male; Mice; Mice, Nude; Nanocapsules; Neoplasms, Experimental; Protein Kinase C; Staurosporine; Treatment Outcome | 2013 |
TrkA kinase inhibitors from a library of modified and isosteric Staurosporine aglycone.
Topics: Animals; Antineoplastic Agents; Carbazoles; Male; Molecular Conformation; Neoplasms, Experimental; Protein Kinase Inhibitors; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor, trkA; Small Molecule Libraries; Staurosporine; Stereoisomerism; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2008 |
p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Bone Neoplasms; cdc25 Phosphatases; Cell Cycle Proteins; Cell Division; Cell Survival; Cells, Cultured; Cisplatin; DNA Damage; DNA Repair; DNA-Binding Proteins; Doxorubicin; G2 Phase; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Knockout; Mice, Nude; Mitosis; Neoplasms, Experimental; Osteosarcoma; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase C; Protein Kinases; Protein Serine-Threonine Kinases; S Phase; Signal Transduction; Staurosporine; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Ultraviolet Rays | 2007 |
Role of protein kinase C and cytokines on the function and production of cytolytic granules in alpha CD3-activated killer-cell-mediated killing of tumor cells.
Topics: Alkaloids; Animals; Antibodies; Antibody-Dependent Cell Cytotoxicity; CD3 Complex; Cytokines; Cytoplasmic Granules; Cytotoxicity, Immunologic; Female; Granzymes; Immunotherapy, Adoptive; Killer Cells, Natural; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Protein Kinase C; Serine Endopeptidases; Staurosporine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1993 |
Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C.
Topics: Alkaloids; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Division; Drug Synergism; Male; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Inbred Strains; Mice, Nude; Mitomycin; Neoplasm Transplantation; Neoplasms, Experimental; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 1993 |
The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251.
Topics: Administration, Oral; Animals; Antibiotics, Antineoplastic; Cell Line; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Fluorouracil; Injections, Intravenous; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Protein Kinases; Staurosporine; Tumor Cells, Cultured | 1995 |
Antitumor activity of the new selective protein kinase C inhibitor 4'-N-benzoyl staurosporine on murine and human tumor models.
Topics: Animals; Antineoplastic Agents; Diet; Female; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 1995 |
Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01.
Topics: Alkaloids; Animals; Antineoplastic Agents; Dogs; Dose-Response Relationship, Drug; Male; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Pancreatic Neoplasms; Rats; Rats, Sprague-Dawley; Staurosporine; Tissue Distribution; Transplantation, Heterologous | 1999 |
Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Cells, Cultured; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Enzyme Inhibitors; Genotype; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Protein Kinase C; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2001 |
UCN-01 (7-hydoxystaurosporine) inhibits in vivo growth of human cancer cells through selective perturbation of G1 phase checkpoint machinery.
Topics: Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; CDC2-CDC28 Kinases; Cell Division; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; DNA, Neoplasm; Drug Resistance, Neoplasm; G1 Phase; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Retinoblastoma Protein; Staurosporine; Transplantation, Heterologous | 2001 |
Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models.
Topics: Alkaloids; Animals; Antineoplastic Agents; Cell Division; Down-Regulation; ErbB Receptors; Humans; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Oncogenes; Protein Kinase C; Staurosporine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1991 |